(Q34156542)

31 July 2017

1 reference

title

Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches (English)

1 reference

31 July 2017

Michael Sendtner

2

0 references

author name string

Hans Thoenen

series ordinal

1

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 November 2002

1 reference

31 July 2017

1 reference

31 July 2017

volume

5 Suppl

1 reference

31 July 2017

page(s)

1046-1050

1 reference

https://scigraph.springernature.com/pub.10.1038/nn938

31 July 2017

exact match

0 references

cites work

The nerve growth factor family

1 reference

7 January 2021

Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system

1 reference

7 January 2021

Neurotrophin signal transduction in the nervous system

1 reference

7 January 2021

Nerve growth factor signaling, neuroprotection, and neural repair

1 reference

7 January 2021

The many faces of p75NTR.

1 reference

7 January 2021

Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases

1 reference

7 January 2021

Nerve growth factor and Alzheimer's disease

1 reference

7 January 2021

Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor

1 reference

7 January 2021

Neurotrophic factors: from molecule to man.

1 reference

7 January 2021

The response of motoneurons to neurotrophins

1 reference

7 January 2021

Ciliary neurotrophic factor prevents degeneration of motor neurons in mouse mutant progressive motor neuronopathy

1 reference

7 January 2021

Arrest of motor neuron disease in wobbler mice cotreated with CNTF and BDNF

1 reference

7 January 2021

Pharmacokinetics of intrathecally applied BDNF and effects on spinal motoneurons.

1 reference

7 January 2021

Ligand-induced down-regulation of Trk messenger RNA, protein and tyrosine phosphorylation in rat cortical neurons

1 reference

7 January 2021

Neurotrophins and synaptic plasticity

1 reference

7 January 2021

Electrical activity and development of neural circuits

1 reference

7 January 2021

Critical periods during sensory development

1 reference

7 January 2021

BDNF and epilepsy: too much of a good thing?

1 reference

7 January 2021

Adenoviral gene transfer of ciliary neurotrophic factor and brain-derived neurotrophic factor leads to long-term survival of axotomized motor neurons

1 reference

7 January 2021

Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease

1 reference

7 January 2021

Recent advances in inducible gene expression systems

1 reference

7 January 2021

Tetracycline-regulated gene expression in the brain

1 reference

7 January 2021

Stem cells--hype and hope

1 reference

7 January 2021

BDNF regulates the maturation of inhibition and the critical period of plasticity in mouse visual cortex

1 reference

7 January 2021

Exercise: a behavioral intervention to enhance brain health and plasticity

1 reference

7 January 2021

Circulating insulin-like growth factor I mediates effects of exercise on the brain.

1 reference

7 January 2021

Circulating insulin-like growth factor I mediates the protective effects of physical exercise against brain insults of different etiology and anatomy.

1 reference

7 January 2021

Robust and efficient regulation of transgene expression in vivo by improved tetracycline-dependent lentiviral vectors

1 reference

7 January 2021

TrkB gene transfer protects retinal ganglion cells from axotomy-induced death in vivo.

1 reference

7 January 2021

Distinctive features of Trk neurotrophin receptor transactivation by G protein-coupled receptors.

1 reference

7 January 2021

Pharmacology of neurotrophic factors

1 reference

7 January 2021

A new concept in neurodegeneration: TNFalpha is a silencer of survival signals

1 reference

7 January 2021

A phase I study of recombinant human ciliary neurotrophic factor (rHCNTF) in patients with amyotrophic lateral sclerosis. The ALS CNTF Treatment Study (ACTS) Phase I-II Study Group

1 reference

7 January 2021

A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. rhCNTF ALS Study Group

1 reference

7 January 2021

A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group

1 reference

7 January 2021

Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients

1 reference

7 January 2021

Neuroprotective gene therapy for Huntington's disease using a polymer encapsulated BHK cell line engineered to secrete human CNTF.

1 reference

7 January 2021

Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease

1 reference

7 January 2021

Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group

1 reference

7 January 2021

Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial. rhNGF Clinical Investigator Group

1 reference

7 January 2021

A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291

1 reference

7 January 2021

Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathy.

1 reference

7 January 2021

A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF Study Group (Phase III)

1 reference

7 January 2021

A phase I/II trial of recombinant methionyl human brain derived neurotrophic factor administered by intrathecal infusion to patients with amyotrophic lateral sclerosis.

1 reference

7 January 2021

A double-blind placebo-controlled clinical trial of recombinant human brain-derived neurotrophic factor (rhBDNF) in diabetic polyneuropathy

1 reference

7 January 2021

Tolerability of recombinant-methionyl human neurotrophin-3 (r-metHuNT3) in healthy subjects

1 reference

7 January 2021

Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group

1 reference

7 January 2021

A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group

1 reference

7 January 2021

Identifiers

DOI

10.1038/NN938

1 reference

31 July 2017

1 reference